Robert Ghenchev
Director/Board Member at OXFORD BIOMEDICA PLC
Robert Ghenchev active positions
Companies | Position | Start | End |
---|---|---|---|
OXFORD BIOMEDICA PLC | Director/Board Member | 24/06/2019 | - |
EXSCIENTIA PLC | Director/Board Member | 01/05/2020 | - |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Director/Board Member | 01/01/2018 | - |
Portfolio Manager-Equities | 01/01/2021 | - | |
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01/01/2018 | - |
Tempus Labs, Inc.
Tempus Labs, Inc. Information Technology ServicesTechnology Services Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL. | Director/Board Member | 01/05/2019 | - |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | 01/05/2020 | - |
Mission Bio, Inc.
Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Director/Board Member | - | - |
Mightyowl, Inc. | Director/Board Member | - | - |
Novo Holdings Equity Us, Inc. | Corporate Officer/Principal | - | - |
░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Career history of Robert Ghenchev
Former positions of Robert Ghenchev
Companies | Position | Start | End |
---|---|---|---|
░░░░░░ ░ ░░░ ░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Robert Ghenchev
University of Oxford | Graduate Degree |
McGill University | Undergraduate Degree |
Statistics
International
United Kingdom | 6 |
United States | 6 |
Denmark | 3 |
Operational
Director/Board Member | 8 |
Corporate Officer/Principal | 2 |
Portfolio Manager-Equities | 1 |
Sectoral
Health Technology | 4 |
Finance | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
OXFORD BIOMEDICA PLC | Health Technology |
EXSCIENTIA PLC | Health Technology |
Private companies | 9 |
---|---|
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Moelis & Co. (UK) LLP
Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010. | Finance |
Tempus Labs, Inc.
Tempus Labs, Inc. Information Technology ServicesTechnology Services Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL. | Technology Services |
Mission Bio, Inc.
Mission Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA. | Commercial Services |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Finance |
Mightyowl, Inc. | |
Novo Holdings Equity Us, Inc. | |
Quanta Dialysis Technologies, Inc. |
- Stock Market
- Insiders
- Robert Ghenchev
- Experience